Osteoporosis disease is characterized by thinning and deterioration of bone tissue with loss of calcification and density, and it can progress over time. Women and older adults are more at risk for developing osteoporosis. Heredity, low body weight, and chronic use of certain medications (such as steroids) are also risk factors for the disease. Early diagnosis of osteoporosis is vital to maintaining good bone strength and avoid debilitating fractures at an old age. Bone density scan is used to measure bone mineral density (BMD). It is most commonly performed using dual-energy x-ray absorptiometry (DXA or DEXA) or bone densitometry. Biochemical markers of bone turnover have been developed over the past 20 years that are more specific for bone tissue than conventional ones such as total alkaline phosphatase and urinary hydroxyproline. The development and introduction of new biochemical markers of bone metabolism in recent years led to a considerable increase in available laboratory methods. To evaluate the activity of osteoblastic synthesis, alkaline phosphatase and other bone-forming markers with higher tissue specificity such as bone alkaline phosphatase, osteocalcin, and several collagen propeptides are used. Bone degradation (calcium and hydroxyproline markers) can now be detected quickly and reliably with many new serological and urinary markers. Pyridinium derivatives and telopeptides as products of the metabolic activity of osteoclasts have been proved efficacious in diagnosis and therapy control.
The global osteoporosis diagnostics market segmentation is based on product type (bone densitometry systems, and bone remodeling biochemical marker tests).
The global osteoporosis diagnostics market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global osteoporosis diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global osteoporosis diagnostics market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global osteoporosis diagnostics market and profiled in this report include Alere, Inc., BeamMed, Beckman Coulter, Inc., CompuMed, Inc., Diagnostic Medical Systems, Furuno Electric Company, GE Healthcare, Hitachi Medical Systems, Hologic, Immunodiagnostic Systems Ltd., Orion Diagnostica, Quest Diagnostics, Inc., Quidel Corp., Roche Diagnostics, Sectra AB, and Swissray International, Inc.